# Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

> **NCT03468751** · PHASE1 · UNKNOWN · sponsor: **Henlix, Inc** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HLX10

## Key facts

- **NCT ID:** NCT03468751
- **Lead sponsor:** Henlix, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-14
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468751, "Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03468751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*